Shares of Nanobiotix S.A. - Sponsored ADR (NASDAQ:NBTX - Get Free Report) traded up 6% on Wednesday . The company traded as high as $43.99 and last traded at $43.99. Approximately 168,440 shares were traded during mid-day trading, an increase of 105% from the average daily volume of 82,142 shares. The stock had previously closed at $41.51.
Wall Street Analyst Weigh In
NBTX has been the topic of several recent research reports. UBS Group upped their target price on shares of Nanobiotix from $3.50 to $30.00 and gave the stock a "neutral" rating in a research note on Friday, May 1st. HC Wainwright reaffirmed a "buy" rating on shares of Nanobiotix in a research report on Monday, May 18th. Weiss Ratings reiterated a "sell (d-)" rating on shares of Nanobiotix in a research note on Friday, July 17th. Finally, Leerink Partners lifted their target price on Nanobiotix from $37.00 to $46.00 and gave the company an "outperform" rating in a report on Thursday, June 4th. Four equities research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat, the stock currently has a consensus rating of "Moderate Buy" and a consensus target price of $37.33.
Check Out Our Latest Report on NBTX
Nanobiotix Stock Performance
The business's 50 day moving average is $38.80 and its 200 day moving average is $35.73.
Institutional Investors Weigh In On Nanobiotix
Institutional investors and hedge funds have recently made changes to their positions in the business. Royal Bank of Canada increased its position in Nanobiotix by 2,000.0% during the 4th quarter. Royal Bank of Canada now owns 2,625 shares of the company's stock worth $61,000 after purchasing an additional 2,500 shares during the period. Marshall Wace LLP acquired a new position in Nanobiotix during the fourth quarter worth $220,000. Finally, Millennium Management LLC acquired a new position in Nanobiotix during the fourth quarter worth $390,000. 38.81% of the stock is owned by hedge funds and other institutional investors.
Nanobiotix Company Profile
(
Get Free Report)
Nanobiotix is a clinical-stage biotechnology company headquartered in Paris, France, specializing in the development of novel nanopharmaceuticals to improve cancer treatment. The company's lead product, NBTXR3, is a first-in-class radioenhancer composed of hafnium oxide nanoparticles designed to amplify the effect of radiotherapy on tumor cells while sparing surrounding healthy tissue. Nanobiotix has established clinical programs across multiple cancer indications, including soft tissue sarcoma, head and neck cancer, and hepatocellular carcinoma.
Since its inception, Nanobiotix has advanced NBTXR3 through pivotal trials and secured CE Mark approval in Europe for the treatment of soft tissue sarcoma.
See Also
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Before you consider Nanobiotix, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Nanobiotix wasn't on the list.
While Nanobiotix currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Nuclear energy is entering a new growth cycle as rising power demand, expanding data centers, and renewed policy support bring the sector back into focus. After strong gains in recent years, the most impactful phase of nuclear investment may still be ahead.
This report highlights seven nuclear energy stocks positioned across the value chain—combining near-term revenue with long-term upside as next-generation technologies scale. Click the link below to unlock the full list.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
